WallStSmart

Amgen Inc (AMGN)vsWipro Limited ADR (WIT)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Wipro Limited ADR generates 2373% more annual revenue ($908.92B vs $36.75B). AMGN leads profitability with a 21.0% profit margin vs 14.6%. AMGN appears more attractively valued with a PEG of 2.33. AMGN earns a higher WallStSmart Score of 70/100 (B-).

AMGN

Strong Buy

70

out of 100

Grade: B-

Growth: 8.0Profit: 8.5Value: 10.0Quality: 5.0
Piotroski: 4/9

WIT

Buy

53

out of 100

Grade: C-

Growth: 4.0Profit: 6.5Value: 7.3Quality: 7.3
Piotroski: 5/9Altman Z: 3.52
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

AMGNUndervalued (+46.8%)

Margin of Safety

+46.8%

Fair Value

$665.50

Current Price

$353.93

$311.57 discount

UndervaluedFair: $665.50Overvalued
WITSignificantly Overvalued (-171.6%)

Margin of Safety

-171.6%

Fair Value

$0.88

Current Price

$2.09

$1.21 premium

UndervaluedFair: $0.88Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

AMGN5 strengths · Avg: 9.6/10
Return on EquityProfitability
106.1%10/10

Every $100 of equity generates 106 in profit

Operating MarginProfitability
30.5%10/10

Strong operational efficiency at 30.5%

EPS GrowthGrowth
112.1%10/10

Earnings expanding 112.1% YoY

Market CapQuality
$187.83B9/10

Large-cap with strong market position

Profit MarginProfitability
21.0%9/10

Keeps 21 of every $100 in revenue as profit

WIT4 strengths · Avg: 9.0/10
Free Cash FlowQuality
$37.93B10/10

Generating 37.9B in free cash flow

Altman Z-ScoreHealth
3.5210/10

Safe zone — low bankruptcy risk

P/E RatioValuation
16.1x8/10

Attractively priced relative to earnings

Price/BookValuation
2.3x8/10

Reasonable price relative to book value

Areas to Watch

AMGN2 concerns · Avg: 3.0/10
PEG RatioValuation
2.334/10

Expensive relative to growth rate

Price/BookValuation
22.0x2/10

Trading at 22.0x book value

WIT2 concerns · Avg: 3.0/10
PEG RatioValuation
2.434/10

Expensive relative to growth rate

EPS GrowthGrowth
-7.2%2/10

Earnings declined 7.2%

Comparative Analysis Report

WallStSmart Research

Bull Case : AMGN

The strongest argument for AMGN centers on Return on Equity, Operating Margin, EPS Growth. Profitability is solid with margins at 21.0% and operating margin at 30.5%.

Bull Case : WIT

The strongest argument for WIT centers on Free Cash Flow, Altman Z-Score, P/E Ratio.

Bear Case : AMGN

The primary concerns for AMGN are PEG Ratio, Price/Book.

Bear Case : WIT

The primary concerns for WIT are PEG Ratio, EPS Growth.

Key Dynamics to Monitor

AMGN profiles as a mature stock while WIT is a value play — different risk/reward profiles.

AMGN carries more volatility with a beta of 0.42 — expect wider price swings.

AMGN is growing revenue faster at 8.6% — sustainability is the question.

WIT generates stronger free cash flow (37.9B), providing more financial flexibility.

Bottom Line

AMGN scores higher overall (70/100 vs 53/100), backed by strong 21.0% margins. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Amgen Inc

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Amgen Inc. (formerly Applied Molecular Genetics Inc.) is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. Focused on molecular biology and biochemistry, its goal is to provide a healthcare business based on recombinant DNA technology.

Visit Website →

Wipro Limited ADR

TECHNOLOGY · INFORMATION TECHNOLOGY SERVICES · USA

Wipro Limited is a global information technology (IT), consulting and business process services company. The company is headquartered in Bengaluru, India.

Want to dig deeper into these stocks?